Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70219 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Andy Bowe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Humana Healthcare Research, Inc, Louisville, Kentucky, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit nennt 61 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims To compare treatment persistence and augmentation in adults with type 2 diabetes initiating glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor therapy, including subgroups with cardiovascular disease and obesity. Materials and Methods Using Humana Healthcare Research claims data, we identified adults with type 2 diabetes newly initiating GLP‐1 RA or SGLT2i therapy between 1 January, 2018, and 30 June 2022. Eligible patients had >12 months of continuous enrollment before and after the index date (first GLP‐1 RA or SGLT2i claim). Persistence was measured over 12 months post‐index, defined by a therapy gap
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Humana Healthcare Research, Inc, Louisville, Kentucky, USA.
- Humana Pharmacy Solutions, Humana Inc, Louisville, Kentucky, USA.
ORCID-Profile: Suzanne Dixon
Zitieren
APA
Bowe, A., Hayes, M., John, I., Diaz, M., Dixon, S., & Poonawalla, I. (2026). Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70219
Vancouver
Bowe A, Hayes M, John I, Diaz M, Dixon S, Poonawalla I. Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70219
BibTeX
@article{Bowe2026,
author = {Bowe, Andy and Hayes, Mary and John, Isha and Diaz, Monica and Dixon, Suzanne and Poonawalla, Insiya},
title = {Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70219}
}
EUVIMED